PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT • 2.1 Preface • 2.2 Preface • 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE • Market ecosystem • Market characteristics • Market segmentation analysis PART 04: MARKET SIZING • Market definition • Market sizing 2018 • Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS • Bargaining power of buyers • Bargaining power of suppliers • Threat of new entrants • Threat of substitutes • Threat of rivalry • Market condition PART 06: MARKET SEGMENTATION BY TYPE • Market segmentation by type • Comparison by type • Cardiogenic pulmonary edema - Market size and forecast 2018-2023 • Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023 • Market opportunity by type PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE • Geographic segmentation • Geographic comparison • North America - Market size and forecast 2018-2023 • Europe - Market size and forecast 2018-2023 • Asia - Market size and forecast 2018-2023 • ROW - Market size and forecast 2018-2023 • Key leading countries • Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES • Market drivers • Market challenges PART 11: MARKET TRENDS • Increasing use of biomarkers for disease diagnosis • Strategic alliances • Increase in funding for research on respiratory diseases PART 12: VENDOR LANDSCAPE • Overview • Landscape disruption • Competitive scenario PART 13: VENDOR ANALYSIS • Vendors covered • Vendor classification • Market positioning of vendors • AbbVie Inc. • Bausch Health Companies, Inc. • Johnson & Johnson Services Inc. • Lupin Ltd. • Merck & Co., Inc. • Mylan NV • Novartis AG • Pfizer Inc. • Sanofi • Teva Pharmaceutical Industries Ltd. PART 14: APPENDIX • Research methodology • List of abbreviations • Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by type Exhibit 20: Cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%) Exhibit 22: Non-cardiogenic pulmonary edema - Market size and forecast 2018-2023 ($ millions) Exhibit 23: Non-cardiogenic pulmonary edema - Year-over-year growth 2019-2023 (%) Exhibit 24: Market opportunity by type Exhibit 25: Customer landscape Exhibit 26: Market share by geography 2018-2023 (%) Exhibit 27: Geographic comparison Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 29: North America - Year-over-year growth 2019-2023 (%) Exhibit 30: Top 3 countries in North America Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 32: Europe - Year-over-year growth 2019-2023 (%) Exhibit 33: Top 3 countries in Europe Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: Top 3 countries in Asia Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 38: ROW - Year-over-year growth 2019-2023 (%) Exhibit 39: Top 3 countries in ROW Exhibit 40: Key leading countries Exhibit 41: Market opportunity Exhibit 42: Impact of drivers and challenges Exhibit 43: Vendor landscape Exhibit 44: Landscape disruption Exhibit 45: Vendors covered Exhibit 46: Vendor classification Exhibit 47: Market positioning of vendors Exhibit 48: AbbVie Inc. - Vendor overview Exhibit 49: AbbVie Inc. - Business segments Exhibit 50: AbbVie Inc. - Organizational developments Exhibit 51: AbbVie Inc. - Geographic focus Exhibit 52: AbbVie Inc. - Key offerings Exhibit 53: AbbVie Inc. - Key customers Exhibit 54: Bausch Health Companies Inc. - Vendor overview Exhibit 55: Bausch Health Companies Inc. - Business segments Exhibit 56: Bausch Health Companies Inc. - Organizational developments Exhibit 57: Bausch Health Companies Inc. - Geographic focus Exhibit 58: Bausch Health Companies Inc. - Segment focus Exhibit 59: Bausch Health Companies Inc. - Key offerings Exhibit 60: Bausch Health Companies Inc. - Key customers Exhibit 61: Johnson & Johnson Services, Inc. - Vendor overview Exhibit 62: Johnson & Johnson Services, Inc. - Business segments Exhibit 63: Johnson & Johnson Services, Inc. - Organizational developments Exhibit 64: Johnson & Johnson Services, Inc. - Geographic focus Exhibit 65: Johnson & Johnson Services, Inc. - Segment focus Exhibit 66: Johnson & Johnson Services, Inc. - Key offerings Exhibit 67: Johnson & Johnson Services, Inc. - Key customers Exhibit 68: Lupin Ltd. - Vendor overview Exhibit 69: Lupin Ltd. - Business segments Exhibit 70: Lupin Ltd. - Organizational developments Exhibit 71: Lupin Ltd. - Geographic focus Exhibit 72: Lupin Ltd. - Key offerings Exhibit 73: Lupin Ltd. - Key customers Exhibit 74: Merck & Co. Inc. - Vendor overview Exhibit 75: Merck & Co. Inc. - Business segments Exhibit 76: Merck & Co. Inc. - Organizational developments Exhibit 77: Merck & Co. Inc. - Geographic focus Exhibit 78: Merck & Co. Inc. - Segment focus Exhibit 79: Merck & Co. Inc. - Key offerings Exhibit 80: Merck & Co. Inc. - Key customers Exhibit 81: Mylan NV - Vendor overview Exhibit 82: Mylan NV - Product segments Exhibit 83: Mylan NV - Organizational developments Exhibit 84: Mylan NV - Geographic focus Exhibit 85: Mylan NV - Segment focus Exhibit 86: Mylan NV - Key offerings Exhibit 87: Mylan NV - Key customers Exhibit 88: Novartis AG - Vendor overview Exhibit 89: Novartis AG - Business segments Exhibit 90: Novartis AG - Organizational developments Exhibit 91: Novartis AG - Geographic focus Exhibit 92: Novartis AG - Segment focus Exhibit 93: Novartis AG - Key offerings Exhibit 94: Novartis AG - Key customers Exhibit 95: Pfizer Inc. - Vendor overview Exhibit 96: Pfizer Inc. - Business segments Exhibit 97: Pfizer Inc. - Organizational developments Exhibit 98: Pfizer Inc. - Geographic focus Exhibit 99: Pfizer Inc. - Segment focus Exhibit 100: Pfizer Inc. - Key offerings Exhibit 101: Pfizer Inc. - Key customers Exhibit 102: Sanofi - Vendor overview Exhibit 103: Sanofi - Business segments Exhibit 104: Sanofi - Organizational developments Exhibit 105: Sanofi - Geographic focus Exhibit 106: Sanofi - Segment focus Exhibit 107: Sanofi - Key offerings Exhibit 108: Sanofi - Key customers Exhibit 109: Teva Pharmaceutical Industries Ltd. - Vendor overview Exhibit 110: Teva Pharmaceutical Industries Ltd. - Business segments Exhibit 111: Teva Pharmaceutical Industries Ltd. - Organizational developments Exhibit 112: Teva Pharmaceutical Industries Ltd. - Segment focus Exhibit 113: Teva Pharmaceutical Industries Ltd. - Key offerings Exhibit 114: Teva Pharmaceutical Industries Ltd. - Key customers Exhibit 115: Validation techniques employed for market sizing Exhibit 116: Definition of market positioning of vendors  

AbbVie Inc., Bausch Health Companies Inc., Johnson & Johnson Services Inc., Lupin Ltd., Merck & Co. Inc., Mylan NV, Novartis AG, Pfizer Inc., Sanofi, and Teva Pharmaceutical Industries Ltd.